| Naslov: | Suboptimal management of hypercholesterolemia in countries with high or very high cardiovascular risk : findings from the international DISCOVERY study |
|---|
| Avtorji: | ID Šabovič, Mišo (Avtor)
ID Pejkov, Hristo (Avtor)
ID Caraus, Alexandru (Avtor)
ID Gruev, Ivan (Avtor)
ID Vintilă, Vlad Damian (Avtor)
ID Csanádi, Zoltán (Avtor)
ID Batjargal, Sodgerel (Avtor)
ID Kovačević -Preradović, Tamara (Avtor)
ID Kusljugić, Zumreta (Avtor)
ID Kuprešak, Draško (Avtor), et al. |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (921,50 KB)
MD5: ACCAAF9FDB8DA94C130946962640EAE5
 URL - Izvorni URL, za dostop obiščite https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2025.1665059/full
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKC LJ - Univerzitetni klinični center Ljubljana
|
|---|
| Povzetek: | Introduction: The 2019 ESC/EAS guidelines introduced stricter low-density lipoprotein cholesterol (LDL-C) targets, particularly for patients at high and very high cardiovascular (CV) risk. However, data on the implementation of these targets in real-world clinical practice—especially in countries with high/very high CV risk—remain limited. The DISCOVERY study aimed to assess LDL-C management, lipid-lowering therapy (LLT) use, and guideline adherence across multiple countries in Central and Eastern Europe and Central Asia. Methods: This prospective, observational, multicenter study enrolled adult patients with hypercholesterolemia (HCL) from 10 countries grouped into three regions. Data was collected at baseline and after 12 weeks of follow-up. LLT patterns, LDL-C levels, target attainment (both investigator-defined and 2019 ESC/EAS-recommended), and physician adherence to guidelines were analyzed. Results: A total of 6,447 patients were included; 53.2% were female, and the mean age was 60.5 ± 11.9 years. Most patients (66%) were in secondary prevention. At baseline, 36.8% had been treated with LLT. After the first visit, treatment was changed in 78% of patients, but only 42.4% received highintensity statins and 9.3% received statin-ezetimibe combinations at followup. LDL-C target achievement was poor: only 5.6% of patients met the guideline-recommended LDL-C goals, compared to 45.5% who met physician-defined targets. Among patients with ASCVD, only 3.3% achieved guideline LDL-C targets. The most significant gap was observed between guideline recommendations and physician-set LDL-C goals. No significant difference in LDL-C target attainment was observed between specialists and general practitioners. Discussion: The DISCOVERY study reveals suboptimal LDL-C control and low adherence to the 2019 ESC/EAS guidelines in routine practice across countries with high/very high CV risk. These findings highlight the urgent need for strategies to improve physician awareness, promote intensive LLT use, and close the gap between guidelines and clinical practice. A paradigm shift toward proactive LDL-C management is essential to reduce residual CV risk in these populations. |
|---|
| Ključne besede: | LDL-C, hypercholesterolemia, lipid-lowering therapy, ESC/EAS guidelines, cardiovascular risk, real-world evidence, statins, ezetimibe |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Leto izida: | 2025 |
|---|
| Št. strani: | str. 1-11 |
|---|
| Številčenje: | Vol. 12, [article no.] 1665059 |
|---|
| PID: | 20.500.12556/DiRROS-28735  |
|---|
| UDK: | 616.1 |
|---|
| ISSN pri članku: | 2297-055X |
|---|
| DOI: | 10.3389/fcvm.2025.1665059 |
|---|
| COBISS.SI-ID: | 270944259 |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Opis vira z dne 9. 3. 2026;
|
|---|
| Datum objave v DiRROS: | 31.03.2026 |
|---|
| Število ogledov: | 34 |
|---|
| Število prenosov: | 15 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
